Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Narrowing Pipelines Lower Profits Of Japan's Big Three Pharmaceutical Outfits

This article was originally published in PharmAsia News

Executive Summary

Thinning drug pipelines of Japan's major pharmaceutical companies began to have an effect on company net profits during the first quarter of the fiscal year. Daiichi Sankyo, Eisai and Takeda each reported a profit decline, with part of the problem due to the cost of recent acquisitions and/or a fluctuating yen. But Takeda also got hit with a delay in U.S. approval of a major diabetes drug and Eisai saw declining sales for its major Alzheimer's drug. All three companies, however, maintained their projected earnings through next March. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts